Tectonic initiates Phase 1B for TX45 in Group 2 PH with HFpEF
Tectonic Therapeutic Announces Participation at Investor Conferences in March
Tectonic Announces Start of First Clinical Program for GPCR-Targeted Biologic
BOSTON--(BUSINESS WIRE)--Tectonic Therapeutic, Inc. a pre-clinical stage biotechnology company transforming the discovery of novel GPCR-targeted therapies (G-Protein Coupled Receptors), today announced the promotion of Senior Vice President, Head of Research, Peter McNamara, PhD, to Chief Scientific Officer as well as the appointments of Barry Rubenstein as Senior Vice President, People and Culture and Washington Alves as Vice President, Biologics Manufacturing.
After managing asthma drug Dupixent at Regeneron, Marcella Ruddy, M.D., is leaving the Big Pharma for biotech Tectonic Therapeutic.